# EDGAR Filing Document

**Accession Number:** 0001660046
**File Stem:** 0001213900-26-049254
**Filing Date:** 2026-4
**Character Count:** 5432
**Document Hash:** ca8d37395d8d60f5cfc213d50e962d8e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-049254.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001213900-26-049254

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Savarirayan Ravi
- **CENTRAL INDEX KEY:** 0002131385

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38104
- **FILM NUMBER:** 26915551

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON
- **NON US STATE TERRITORY:** VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuron Ltd
- **CENTRAL INDEX KEY:** 0001660046
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 03 9824 5254

**MAIL ADDRESS:**
- **STREET 1:** 62 LYGON STREET
- **STREET 2:** LEVEL 3
- **CITY:** CARLTON, VICTORIA
- **STATE:** C3
- **ZIP:** 3053

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Savarirayan Ravi<br><sub>(Last) (First) (Middle)</sub><br>LEVEL 3, 62 LYGON STREET<br><sub>(Street)</sub><br>CARLTON VIC, AUSTRALIA 3053<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Immuron Ltd [ IMRN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 409090 | D |  |
| Ordinary Shares | 468750 | I | Joint ownership with [Sophie Beaumont] |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Options | 2025-12-08<sup>(1)</sup> | 2028-08-20 | Ordinary Shares | 333333 | 0.1040<sup>(3)</sup> | D |  |
| Options | 2025-11-24<sup>(2)</sup> | 2029-10-03 | Ordinary Shares | 1000000 | 0.0789<sup>(4)</sup> | D |  |

---

### Footnotes:

(1) The option became exercisable as to 333,333 shares on December 8, 2025, and becomes exercisable as to the remaining 333,333 shares on December 8, 2026, and 333,334 shares on December 8, 2027.

(2) The option will become exercisable as to 333,333 shares on November 26, 2026; 333,333 shares on November 24, 2027, and 333,334 shares on November 24, 2028.

(3) The exercise price of this option, originally denominated in Australian dollar ("AUD") in the amount of AUD $0.145 is presented in the table in U.S.dollars ("USD") based on the exchange rate reported by the Reserve Bank of Australia on April 28, 2026, which was AUD 1.00 = USD 0.7172.

(4) The exercise price of this option, originally denominated in Australian dollar ("AUD") in the amount of AUD $0.110 is presented in the table in U.S.dollars ("USD") based on the exchange rate reported by the Reserve Bank of Australia on April 28, 2026, which was AUD 1.00 = USD 0.7172.

**Signature:** /s/ Ravi Savarirayan  
**Date:** 2026-04-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**